首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   6770篇
  免费   480篇
  国内免费   156篇
医药卫生   7406篇
  2024年   12篇
  2023年   107篇
  2022年   197篇
  2021年   274篇
  2020年   243篇
  2019年   241篇
  2018年   257篇
  2017年   206篇
  2016年   279篇
  2015年   272篇
  2014年   414篇
  2013年   475篇
  2012年   352篇
  2011年   326篇
  2010年   248篇
  2009年   346篇
  2008年   363篇
  2007年   373篇
  2006年   313篇
  2005年   277篇
  2004年   222篇
  2003年   173篇
  2002年   156篇
  2001年   155篇
  2000年   119篇
  1999年   116篇
  1998年   123篇
  1997年   88篇
  1996年   59篇
  1995年   68篇
  1994年   66篇
  1993年   48篇
  1992年   49篇
  1991年   33篇
  1990年   27篇
  1989年   40篇
  1988年   37篇
  1987年   18篇
  1986年   35篇
  1985年   31篇
  1984年   30篇
  1983年   16篇
  1982年   24篇
  1981年   26篇
  1980年   25篇
  1979年   19篇
  1978年   9篇
  1977年   6篇
  1976年   7篇
  1972年   2篇
排序方式: 共有7406条查询结果,搜索用时 15 毫秒
1.
2.

Background

Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.

Patients and Methods

We conducted a multicenter retrospective analysis in the Triveneto region of Italy.

Results

One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.

Conclusion

This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined.  相似文献   
3.
Palliative whole brain radiotherapy (WBRT) is often recommended in the management of multiple brain metastases. Allowing for WBRT waiting time, duration of the WBRT course and time to clinical response, it may take 6 weeks from the point of initial assessment for a benefit from WBRT to manifest. Patients who die within 6 weeks (‘early death’) may not benefit from WBRT and may instead experience a decline in quality of life. This study aimed to develop a prognostic index (PI) that identifies the subset of patients with lung cancer with multiple brain metastases who may not benefit from WBRT because of ‘early death’. The medical records of patients with lung cancer who had WBRT recommended for multiple brain metastases over a 10-year period were retrospectively reviewed. Patients were classified as either having died within 6 weeks or having lived beyond 6 weeks. Potential prognostic indicators were evaluated for correlation with ‘early death’. A PI was constructed by modelling the survival classification to determine the contribution of these factors towards shortened survival. Of the 275 patients recommended WBRT, 64 (23.22%) died within 6 weeks. The main prognostic factor predicting early death was Eastern Cooperative Oncology Group (ECOG) status >2. Patients with a high PI score (>13) were at higher risk of ‘early death’. Twenty-three per cent of patients died prior to benefit from WBRT. ECOG status was the most predictive for ‘early death’. Other factors may also contribute towards a poor outcome. With further refinement and validation, the PI could be a valuable clinical decision tool.  相似文献   
4.
Survival after resection of colorectal liver metastases has traditionally been associated with clinicopathologic factors. We sought to investigate whether echogenicity of colorectal liver metastasis as assessed by intraoperative ultrasound (IOUS) was a prognostic factor after hepatic resection. Prospective data on tumor IOUS appearance were collected in 84 patients who underwent hepatic resection for colorectal liver metastasis. Images were digitally recorded, blindly reviewed, and scored for echogenicity (hypo-, iso-, or hyperechoic). The median tumor number was 1 and the median tumor size was 5.0 cm. At the time of surgery, the IOUS appearance of the colorectal liver metastases were hypoechoic in 35 (41.7%) patients, isoechoic in 37 (44.0%) patients, and hyperechoic in 12 (14.3%) patients. Traditional clinicopathologic prognostic factors were similarly distributed among the three echogenicity groups (all p > 0.05). Patients with a hypoechoic lesion had a significantly shorter median survival (30.2 months) compared with patients who had either an isoechoic (53.2 months) or hyperechoic (42.3 months) lesion (p = 0.005). The 5-year survival after hepatic resection of colorectal liver metastasis was also associated with the echogenic appearance of the lesion (hypoechoic 14.4 vs isoechoic 37.4 vs hyperechoic 46.2%) (p < 0.05). Intraoperative ultrasound echogenicity should be considered a prognostic factor after hepatic resection of metastatic colorectal cancer. This study was presented at the 47th annual meeting of The Society for Surgery of the Alimentary Tract, Los Angeles, CA, USA, 22 May 2006.  相似文献   
5.
Abstract:   A 66-year-old man was referred to our hospital with chest discomfort and shortness of breath. Seven months previously he had undergone a laparoscopic left nephroureterectomy for a left renal pelvic tumor and was given two cycles of adjuvant chemotherapy (methotrexate, epirubicin and cisplatin). Echocardiogram showed an 8-mm sized mass extending from the right atrium into the right ventricle. On computed tomography, multiple lung tumors, as well as the right atrial and ventricular mass, were seen. The patient died of acute heart failure caused by right ventricular outflow obstruction. On autopsy, a right atrial and ventricular metastasis of the initial transitional cell carcinoma was found. The patient's cause of death was acute heart failure as a result of cardiac metastasis of his initial renal pelvic carcinoma.  相似文献   
6.
Clusterlike Headache as a First Sign of Brain Metastases of Lung Cancer   总被引:1,自引:0,他引:1  
Dr.  J. Tajti  MD  PhD ; Dr.  K. Sas  MD ; Dr.  D. Szok  MD ; Dr.  E. Vörös  MD ; Dr.  L. Vécsei  MD  DSc 《Headache》1996,36(4):259-260
We report on a patient with clusterlike headache and multiple brain metastases of lung cancer. Initially, cluster headache was suggested clinically by characteristic symptoms without any focal central nervous system signs. However, magnetic resonance imaging demonstrated multiple brain metastases. It is possible that tumor necrosis factor may have played a role in initiating the clusterlike headache.  相似文献   
7.
8.
目的:探讨全肺放疗治疗肺转移癌的价值.方法:1999年3月~2003年5月我院肿瘤科收治24例双肺多发肺转移癌患者,均给予全肺放疗.现对这些患者的临床资料进行总结分析.结果:本组放疗结束时转移瘤CR率为37.5%(9/24),PR率为50.0%(12/24),有效率(PR+CR)达87.5%.原发肿瘤为鼻咽癌、乳腺癌、肝癌、结直肠癌的中位生存期分别为13.5、22.0、10.5月、8.5月.1~2级放射性肺炎发生率为25.0%(6/24);3级为16.7%(2/24);4~5级为0.结论:恶性肿瘤肺多发转移可以采用全肺放疗+局部小野补量治疗,尤其适用于原发肿瘤对放疗中高度敏感、化疗无效的患者,可获得较好疗效.毒副作用可耐受.  相似文献   
9.
Recent studies show comparable results of arthroscopic shoulder stabilization techniques compared with the gold standard open Bankart reconstruction. Great technical advances and ever-increasing surgeon experience have rendered pathology once deemed an indication for open surgery as treatable by arthroscopic means. With this movement toward a more universal application of all-arthroscopic techniques, we might consider the following question: Is there ever a need to open? To answer this question, we must first consider normal anatomy and then appreciate the contribution of deranged pathoanatomy to recurrent instability in each individual case. The surgeon must then determine whether this is best addressed via an arthroscopic or open technique. Arthroscopy, as compared with open stabilization procedures, holds the potential benefits of decreased morbidity rates, early functional rehabilitation, and improved range of motion. Despite potential advantages, arthroscopic stabilization is clearly contraindicated when a significant pathologic lesion contributing to recurrent instability cannot be adequately addressed as a result of the limitations of current techniques or instrumentation. On the basis of this principle, we believe that sizable glenohumeral bone defects remain the only absolute contraindication to an all-arthroscopic approach. Many complicating issues, such as attenuated capsule, humeral avulsion of the glenohumeral ligament lesions, cases of revision surgery, and collision or contact athletes, exist and warrant close attention. We prefer to think of these situations as “challenges” for which both arthroscopic and open surgery should be considered, rather than as true contraindications to arthroscopic shoulder stabilization. We are, by no means, advocating arthroscopic treatment in all cases of shoulder instability, because this would represent a gross oversimplification of the issues at hand. However, we do acknowledge that the steadfast contraindications to arthroscopic shoulder stabilization are decreasing every day.  相似文献   
10.
放射治疗71例骨转移癌止痛效果分析   总被引:2,自引:0,他引:2  
目的观察低于常规剂量的2种分割方式治疗骨转移性疼痛的疗效。方法71例恶性肿瘤晚期骨转移患者,总计93处骨转移灶,根据疼痛程度及行动受限程度,采取2种均低于常规剂量的分割方式进行放射治疗,分别为Dm30Gy/10f/2W,Dm30Gy/6f/2W。观察疼痛缓解情况。结果2种分割方式止痛有效率分别为88%、95%。两组间无显著差异性(P>0.05)。与国内多数文献报告的结果接近。结论低于常规剂量的分割方式对转移性骨痛疗效与常规剂量的分割方式的疗效相当,且简便易行。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号